Clinical trials
Phase 3 Parkinson Disease trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 2 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 5 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Terminated | 7 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 4 |
| Adamas Pharmaceuticals, Inc. | 4 |
| Impax Laboratories, LLC | 4 |
| Eisai Limited | 3 |
| GlaxoSmithKline | 3 |
| Theravance Biopharma | 3 |
| Boehringer Ingelheim | 2 |
| Sumitomo Pharma America, Inc. | 2 |
| University Hospital, Toulouse | 2 |
| ACADIA Pharmaceuticals Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Parkinson Disease | 45 |
| Parkinsonian Disorders | 10 |
| Dyskinesias | 6 |
| Brain Diseases | 4 |
| Central Nervous System Diseases | 4 |
| Movement Disorders | 4 |
| Nervous System Diseases | 4 |
| Neurodegenerative Diseases | 4 |
| Dizziness | 3 |
| Hypotension | 3 |
Trials
Showing 1 to 25 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.